Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ITI-5000 TNBC Vaccine + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Immunomic Therapeutics
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intravenous
01
Overview
ITI-5000 TNBC Vaccine + pembrolizumab is an investigational combination therapy being evaluated for the treatment of early-stage triple-negative breast cancer (TNBC). ITI-5000 is a self-amplifying RNA (saRNA) vaccine delivered via lipid nanoparticles (LNPs). It encodes a fusion protein consisting of two tumor-associated antigens, Human Endogenous Retrovirus-K (HERV-K) and Cancer/Testis Antigen 83 (CT83), fused with Lysosomal-Associated Membrane Protein 1 (LAMP-1) to enhance immune presentation. Pembrolizumab is a programmed death receptor-1 (PD-1) blocking monoclonal antibody. The combination aims to stimulate a robust T-cell response against TNBC cells while overcoming immune checkpoint-mediated suppression.
- Brand names
- Keytruda
- Other names
- ITI-5000 TNBC VaccineITI5000 TNBC VaccineITI 5000 TNBC VaccineVITAL-TNBC Study vaccine combination
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on ITI-5000 TNBC Vaccine + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ITI-5000 TNBC Vaccine + pembrolizumab.